Analysts Set Benitec Biopharma Limited (NASDAQ:BNTC) Price Target at $23.83

Benitec Biopharma Limited (NASDAQ:BNTC) has received an average recommendation of “Buy” from the nine ratings firms that are presently covering the firm, Marketbeat reports. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among analysts that have covered the stock in the last year is $23.83.

A number of brokerages recently weighed in on BNTC. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price objective on shares of Benitec Biopharma in a research report on Monday, May 19th. JMP Securities reaffirmed a “market outperform” rating and set a $20.00 price objective on shares of Benitec Biopharma in a research report on Thursday, May 15th.

Institutional Investors Weigh In On Benitec Biopharma

Several institutional investors have recently added to or reduced their stakes in BNTC. Franklin Resources Inc. boosted its holdings in Benitec Biopharma by 269.0% in the fourth quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company’s stock worth $37,123,000 after acquiring an additional 2,142,643 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Benitec Biopharma by 198.5% during the fourth quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company’s stock worth $33,268,000 after purchasing an additional 1,739,904 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Benitec Biopharma by 134.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company’s stock worth $24,913,000 after purchasing an additional 1,131,129 shares during the period. Infinitum Asset Management LLC lifted its holdings in shares of Benitec Biopharma by 435.7% during the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company’s stock worth $14,636,000 after purchasing an additional 915,000 shares during the period. Finally, Suvretta Capital Management LLC lifted its holdings in shares of Benitec Biopharma by 1.5% during the fourth quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company’s stock worth $113,165,000 after purchasing an additional 130,956 shares during the period. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Stock Performance

Shares of Benitec Biopharma stock opened at $13.16 on Monday. The firm has a market cap of $345.45 million, a P/E ratio of -8.72 and a beta of 0.44. The company has a current ratio of 14.80, a quick ratio of 14.80 and a debt-to-equity ratio of 0.01. Benitec Biopharma has a 12 month low of $6.66 and a 12 month high of $17.15. The stock’s fifty day moving average price is $14.46 and its 200-day moving average price is $12.92.

Benitec Biopharma (NASDAQ:BNTC) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.12. On average, equities research analysts expect that Benitec Biopharma will post -1.48 earnings per share for the current fiscal year.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.